Breast cancer remains a leading cause of cancer-related mortality in women, reflecting
profound disease heterogeneity, metastasis, and therapeutic resistance. Over the last …

Breast cancer is the most frequent malignancy in women worldwide and is curable in~ 70–
80% of patients with early-stage, non-metastatic disease. Advanced breast cancer with …

Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative
breast cancer (BC) with low HER2 expression (ie, 1+ or 2+ and lack of ERBB2 amplification) …

Metabolic rewiring is often considered an adaptive pressure limiting metastasis formation;
however, some nutrients available at distant organs may inherently promote metastatic …

Abstract Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …

Abstract The AURORA US Metastasis Project was established with the goal to identify
molecular features associated with metastasis. We assayed 55 females with metastatic …

Abstract The phosphatidylinositol 3-kinase (PI3K)-Akt and the mammalian target of
rapamycin (mTOR) represent two vital intracellular signaling pathways, which are …

Cancer classification aims to provide an accurate diagnosis of the disease and prediction of
tumor behavior to facilitate oncologic decision making. Traditional breast cancer …

We integrated the genomic sequencing of 1,918 breast cancers, including 1,501 hormone
receptor-positive tumors, with detailed clinical information and treatment outcomes. In 692 …

Breast cancer, the most common type of cancer affecting women, encompasses a collection
of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical …